Allan W. Wolkoff

https://assets.montefioreeinstein.org/profiles/images/physphoto/Wolkoff_Allan_W_MD_2574.jpg

First Name

Allan

Last Name

Wolkoff

NPI

1700961703

Faculty ID

3303

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><span>Dr. Allan Wolkoff's interest in research was sparked when he worked in a biochemistry lab to help pay college bills. He began his medical studies at Dartmouth Medical College and transferred to the Albert Einstein College of Medicine where he obtained his M.D. degree. With the exception of a two year period when he was Clinical Associate in Gastroenterology-Hepatology in the Digestive Disease Branch, National Institute of Arthritis, Metabolism and Digestive Disease, he has remained at Albert Einstein. His early mentor, Irwin M. Arias, M.D. of the National Institutes of Health said of Wolkoff&rsquo;s work, &ldquo;He built an exemplary global reputation in hepatology research, education, training and scholarship. A major participant in the creation of the Marion Bessin Liver Research Center at Albert Einstein, Dr. Wolkoff has taken advantage of the strong, interactive basic science departments and is a leader in bridging understanding of hepatocyte biology with the pathogenesis of acquired and inheritable liver diseases.&rdquo; </span></p>
<p><span>Dr. Wolkoff is a pioneer in the combining of disciplines that inform basic understanding of hepatocyte function and relation to disease and is recognized worldwide for providing new windows into physiology and pathophysiology.&nbsp;</span><span>He has had articles published in over 100 peer-reviewed publications, given many invited lectures and has had continuous NIH-supported research. In addition, he has served on advisory committees of several NIH-supported liver research centers. In 2006, he was presented the AASLD Distinguished Service Award. In 2012, he received the&nbsp;<span>highly prestigious 2012 Distinguished Scientific Achievement Award from the American Liver Foundation.</span></span></p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Diseases of the liver and biliary tract including chronic liver disease, fatty liver disease, hepatitis, inheritable disorders of the liver, drug toxicity, and unexplained jaundice.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Research interests include the mechanism by which the liver removes drugs and other compounds from the circulation and how its dysfunction may lead to drug toxicity.<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

3553

Biography

<p>Allan W. Wolkoff, MD, is Chief, Hepatology, Herman Lopata Chair in Liver Disease Research and Professor, Medicine and Developmental &amp; Molecular Biology at Montefiore Einstein. His clinical focus centers on diseases of the liver and biliary tract, including chronic liver disease, fatty liver disease, hepatitis, inheritable disorders of the liver, drug toxicity and unexplained jaundice.</p><p>Dr. Wolkoff began his medical studies at Dartmouth Medical College and transferred to Einstein, where he earned his Doctor of Medicine in 1972. He completed an internship at Bronx Municipal Hospital Center in 1973 before becoming an Assistant Resident in Medicine until 1974. Following this, Dr. Wolkoff became a Clinical Associate in Gastroenterology-Hepatology at the National Institutes of Health (NIH) until 1976.</p><p>A pioneer in combining disciplines that inform basic understanding of hepatocyte function and relation to disease, Dr. Wolkoff is recognized worldwide for providing new windows into physiology and pathophysiology. His research interests include the mechanism by which the liver removes drugs and other compounds from circulation and how its dysfunction may lead to drug toxicity. He has had articles published in over 100 peer-reviewed publications, given many invited lectures and has had continuous NIH-supported research.</p><p>Dr. Wolkoff has served on advisory committees of several NIH-supported liver research centers. In 2006, he was presented with the American Association for the Study of Liver Diseases (AASLD) Distinguished Service Award. In 2012, he received the highly prestigious Distinguished Scientific Achievement Award from the American Liver Foundation. He was named Physician of the Year by the Greater New York Division of the American Liver Foundation in 2015 and won the National Leadership Award from the American Liver Foundation in 2022.</p>

Is Open Scheduling

Off

Daniel A. Weiser

https://assets.montefioreeinstein.org/profiles/images/Weiser_Daniel_MD_2x.jpg

First Name

Daniel

Last Name

Weiser

NPI

1225239700

Faculty ID

13846

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><span style="text-decoration: underline;"><strong>Childhood cancer research laboratory</strong></span></p>
<p>Our laboratory is focused on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. In such patients with typically incurable cancer, we are striving to identify new approaches to and types of treatment. We have multiple ongoing projects:</p>
<p><strong>+ Identification of biologic drivers of ultra-high-risk neuroblastoma</strong>. Neuroblastoma is one of the most common and deadly childhood cancers. Despite intensive research, there are limited therapeutic strategies for patients with <em>de novo </em>chemotherapy resistance that leads to particularly poor outcomes. We have been studying neuroblastoma since 2009 and are identifying additional biologic drivers of highly lethal tumors.</p>
<p>We compare tumor features from patients with early death from tumor progression compared to those with a maintained complete response. We assess unique histo-morphologic and proteomic features and computationally integrate these data with genomic and transcriptomic datasets to develop a combined predictor of primary refractory disease. Patients with this entity require non-standard and/or intensified treatment. Oncogenic drivers are being characterized in the lab which will facilitate strategies for novel pharmacologic intervention.</p>
<p><strong>+ Characterization of neuroblastoma development from neural crest cells</strong>.&nbsp; We are studying pathways and interactions that results in uncontrolled cell proliferation early in neuroblastoma development with an ultimate goal of identifying new targets and approaches for pharmacologic intervention.</p>
<p><strong>+ Evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma</strong>.&nbsp; With expected outcomes lagging behind those of more common childhood cancers, children with neuroblastoma require new approaches to treatment. Our lab works with multiple international clinical and research consortium groups to perform preclinical studies that substantiate human clinical trials.&nbsp;</p>
<p><strong>+ Detection of circulating tumor DNA in osteosarcoma</strong>. With no reliable non-invasive approach for disease monitoring during and after treatment, we are applying cutting edge next-generation sequencing approaches to identify solid tumors with a blood-based &ldquo;liquid&rdquo; biopsies. This will allow clinicians to assess tumor responsiveness to chemotherapy and predict likelihood of recurrence.</p>
<p><strong>+ Assessment of accelerated aging using miRNA-seq in survivors of childhood cancer</strong>. Chemotherapy has many untoward effects on healthy cells and leads to many signs of accelerated aging in children treated for cancer. Using a known microRNA &ldquo;aging&rdquo; signature discovered at Albert Einstein College of Medicine, we are studying what causes this phenotype in childhood cancer, with a goal of offering improved intervention to minimize long-term toxicity of treatment.</p>
<p><strong><span style="text-decoration: underline;">Physician Summary</span></strong></p>
<p>Daniel A. Weiser, MD, is board-certified in pediatric hematology/oncology with clinical expertise in neuroblastoma and other tumors of the adrenal glands, kidneys, liver, and gonads. He is the medical director of the intra-abdominal solid tumor program at the Children&rsquo;s Hospital at Montefiore and brings together a highly specialized multi-disciplinary care team to provide comprehensive treatment for diverse pediatric malignancies. In addition, Dr. Weiser directs a childhood cancer research laboratory that focuses on the identification of new targeted agents for cancer therapy, especially in the treatment of rare and aggressive malignancies such as neuroblastoma. His research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise for improving management of all patients with solid tumors.</p>
<p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children&rsquo;s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Advances in Neuroblastoma Research Association (ANRA), National Pediatric Cancer Foundation (NPCF), and the American Academy of Pediatrics (AAP). He has received numerous awards including the Brigid Leventhal Special Merit Award from ASCO and the Conquer Cancer Foundation, and a prestigious K12 from the National Cancer Institute for the training of the next generation of physician-scientists in pediatric cancer. Dr. Weiser is actively involved in teaching and mentorship of trainees, and takes great pride in providing advanced and compassionate care to his patients and their families.</p>
<p><strong>Clinical Expertise</strong></p>
<ul>
<li>Neuroblastoma (adrenal tumors)</li>
<li>Wilms tumor (renal tumors)</li>
<li>Hepatoblastoma (liver tumors)</li>
<li>Germ cell tumors (including testicular and ovarian tumors)</li>
<li>Thyroid and other rare tumors</li>
<li>Experimental therapeutics</li>
<li>Cancer genetics and biomarkers</li>
</ul>
<p><strong>Board Certifications</strong></p>
<ul>
<li>Pediatrics</li>
<li>Pediatric Hematology/Oncology</li>
</ul>
<p><strong>Professional Education</strong></p>
<ul>
<li>M.D. &ndash; Stony Brook University, NY</li>
<li>Residency &ndash; Children&rsquo;s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Chief Residency &ndash; Children&rsquo;s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Fellowship &ndash; The Children&rsquo;s Hospital of Philadelphia, PA</li>
</ul>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

DR. Weiser's clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma, and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers.&nbsp;

Research Focus

Dr. Weiser&rsquo;s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser&rsquo;s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others.

Elsevier Profile

EMR ID

5755

Biography

<p>Daniel A. Weiser, MD, is a Medical Director of the Intra-abdominal Solid Tumor Program in the Pediatrics Hematology/Oncology department at Children&rsquo;s Hospital at Montefiore. He is also Associate Professor in the Pediatrics and Genetics departments at the Albert Einstein College of Medicine. His clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers. Dr. Weiser is actively involved in teaching and mentorship of trainees and takes great pride in his active participation in patient care.</p><p>Dr. Weiser received his Bachelor of Science in Neurobiology in 1995 at Haverford College, PA. In 2004, he received his Doctor of Medicine at Stony Brook University School of Medicine, NY. He is currently earning his Master of Science in Translational Research at the University of Pennsylvania. He began a residency in Pediatrics at the New York-Presbyterian, Columbia University in 2007. Dr. Weiser then completed a three-year fellowship in Pediatric Hematology/Oncology at The Children&rsquo;s Hospital of Philadelphia. </p><p>Dr. Weiser&rsquo;s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser&rsquo;s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others. His research has been published in many reviewed journals. </p><p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children&rsquo;s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and the American Academy of Pediatrics (AAP). He has received many awards including the Brigid Leventhal Special Merit Award through ASCO, and he has been awarded a prestigious K12 from the NCI for the training of the next generation of physician-scientists in pediatric cancer.</p><p>He is board certified in Pediatric Hematology/Oncology and General Pediatrics.</p>

Is Open Scheduling

Off

Jacqueline Weingarten-Arams

https://assets.montefioreeinstein.org/profiles/images/physphoto/Weingarten_Jacqueline_MD_420x504.jpg

First Name

Jacqueline

Last Name

Weingarten-Arams

NPI

1558447409

Faculty ID

4831

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Areas

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Elsevier Profile

Lab Website Link

EMR ID

3961

Biography

<p>Jacqueline Weingarten-Arams, MD, is an attending physician and Professor, Pediatrics at Montefiore Einstein. Dr. Weingarten-Arams&rsquo; pediatric critical care expertise focuses on cardiac critical care, acute hypoxemic respiratory failure, nutrition in critical illness and energy expenditure, cardiopulmonary resuscitation (quality CPR) and extracorporeal life support (ECMO).</p><p>After obtaining her Bachelor of Science in nutritional biochemistry at Cornell University in 1982, Dr. Weingarten-Arams earned her Doctor of Medicine at the same institution in 1986. She then completed her pediatric residency at Columbia University in 1990, where she was Chief Resident in her final year. Following this, Dr. Weingarten-Arams completed a fellowship in pediatric critical care medicine at New York Hospital Cornell University Medical College in 1996.</p><p>Dr. Weingarten-Arams research focus includes the use of deliberate simulated practice in improving outcomes in pediatric critical illness, pediatric resuscitation and pediatric airway management. Her other projects involve chronic critical illness, bioethics in pediatric critical care and oxidative injury in respiratory failure. She has been principal investigator and co-investigator on several research projects, and her work has been shared through numerous peer-reviewed publications and invited presentations.</p><p>Dr. Weingarten-Arams is a Diplomate of the National Board of Medical Examiners and the American Board of Pediatrics. She is a Fellow of the American Academy of Pediatrics and the American College of Chest Physicians. She is also a member of several professional organizations, including the American Medical Association, the Pediatric Cardiac Intensive Care Society and the Society of Critical Care Medicine. Dr. Weingarten-Arams has been named in Castle Connolly&rsquo;s &ldquo;Top Doctors: New York Metro Area&rdquo; for multiple years. In 2006, she was inducted into the Leo M. Davidoff Society and in 2019, Dr. Weingarten-Arams won the William Obrinsky Award for Excellence in Medical Student Education.</p>

Is Open Scheduling

Off

Clara Y. Tow

https://assets.montefioreeinstein.org/profiles/images/physphoto/Tow_Clara_MD_420x504.jpg

First Name

Clara

Last Name

Tow

NPI

1174822845

Faculty ID

15844

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Tow is a transplant hepatologist and Assistant Professor of Medicine at Montefiore Medical Center and Albert Einstein College of Medicine. She serves as the Clinical Site Director of Hepatology at the Weiler Division of MMC, Associate Program Director of the Gastroenterology &amp; Liver Diseases Fellowship Program, and the Co-Director of the AECOM Gastroenterology &amp; Hepatology Systems Course.</p>
<p>Dr. Tow holds a B.A. in Biological Sciences from Cornell University College of Arts and Sciences and graduated Phi Beta Kappa and Magna Cum Laude for her work in developmental research. While attending Weill Cornell Medical College, she developed her passion for transplant medicine and was awarded Alpha Omega Alpha and Honors in Research for her characterization of mitochondrial injury during ischemia-reperfusion injury. Dr. Tow completed her internship and residency in Internal Medicine at New York Presbyterian Hospital - Weill Cornell Medical Center, where she served as an education resident, and fellowship in Gastroenterology and Liver Diseases at Montefiore Medical Center. Subsequently she pursued her advanced fellowship training in Transplant Hepatology at New York Presbyterian Hospital &ndash; Columbia University Medical Center.</p>
<p>Dr. Tow has been at Montefiore/Einstein since 2018, where she specializes on the complications of advanced liver diseases, liver cancer, and liver transplant. She believes every patient is an integral part of the Montefiore family and that patient knowledge is power. Her goal is to provide patients and their families the best medical care that is embedded in kindness, dignity, and respect.&nbsp;</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Tow specializes in the treatment of complications of advanced liver diseases, liver cancer, and liver transplant. She believes every patient is an integral part of the Montefiore Einstein family and that patient knowledge is power. Her goal is to provide patients and their families with the best medical care embedded in kindness, dignity, and respect.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Dr. Tow&rsquo;s research focuses on social determinants of health and outcomes related to liver transplantation and the care of advanced liver disease. She has spoken at invited lectures nationally and internationally, and her work has been published in many peer-reviewed journals, books, chapters, review articles, and abstracts.<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

29458

Biography

<p>Clara Y. Tow, MD, is Clinical Site Director, Hepatology, Associate Program Director, Gastroenterology &amp; Liver Diseases Fellowship Program, Co-Course Director, Gastroenterology &amp; Hepatology Systems Course and Assistant Professor, Medicine at Montefiore Einstein. Dr. Tow specializes in the treatment of complications of advanced liver diseases, liver cancer and liver transplant. She believes every patient is an integral part of the Montefiore Einstein family and that patient knowledge is power. Her goal is to provide patients and their families with the best medical care embedded in kindness, dignity and respect.</p><p>After obtaining her Bachelor of Arts in biological sciences from Cornell University College of Arts and Sciences, Dr. Tow earned her Doctor of Medicine from Weill Cornell Medical College. She then completed her internship and residency in internal medicine at NewYork-Presbyterian Hospital, Weill Cornell Medical Center. Following this, she completed a gastroenterology and liver diseases fellowship at Montefiore Medical Center before pursuing her advanced fellowship training in transplant hepatology at NewYork-Presbyterian Hospital.</p><p>Dr. Tow&rsquo;s research focuses on social determinants of health and outcomes related to liver transplantation and the care of advanced liver disease. She has spoken at invited lectures nationally and internationally, and her work has been published in many peer-reviewed journals, books, chapters, review articles and abstracts.</p><p>Dr. Tow is board certified by the American Board of Internal Medicine in transplant hepatology, gastroenterology and internal medicine. She is a member of the American Association for the Study of Liver Diseases (AASLD), the American Society of Transplantation (AST) and the European Association for the Study of the Liver (EASL). She is also a member of the Empire Liver Foundation and a Medical Advisor for the American Liver Foundation. In 2014, Dr. Tow won the Erica C. Jones &amp; Naina Sinha-Gregory Prize in Medicine.</p>

Is Open Scheduling

On

Aaron Zev Tokayer

https://assets.montefioreeinstein.org/profiles/images/Tokayer_Aaron_MD_420x504.jpg

First Name

Aaron

Last Name

Tokayer

NPI

1336220755

Faculty ID

704

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Tokayer received his B.A. in from Yeshiva College and his M.D. from Albert Einstein College of Medicine of Yeshiva University. &nbsp;He completed an internship and residency at the Bronx Municipal Hospital Center and GI and Hepatology fellowship at Johns Hopkins Medical Center. He received an MHS degree in Clinical Epidemiology from Johns Hopkins School of Public Health. Dr. Tokayer then joined the Montefiore GI Faculty in 1992. He has been involved in the spectrum of clinical patient care, endoscopic interventions and teaching in the GI fellowship program. His areas of interest include clinical practice, patient care and education, endoscopic procedures and interventions, functional GI and motility disorders. He is Director of the GI Motility Lab where studies such as Esophageal Manometry,&nbsp; Esophageal Acid Monitoring and Impedance Testing, Ano-rectal Manometry and Defecatory Testing, Hydrogen Breath Testing for Bacterial overgrowth and Carbohydrate Maldigestion , and studies of gastric and intestinal transit. He works closely with colleagues of the Department of Radiology and Nuclear Medicine as well as the Department of Surgery in diagnosing and treating GI motility disorders.</p>

Research Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Is Open Scheduling

Off

Tihomir Stefanec

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/9bfe20f0-2346-11ee-88ab-4d123afddc94.jpg

First Name

Tihomir

Last Name

Stefanec

NPI

1396729976

Faculty ID

11731

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>I am interested in Internal Medicine, Critical Care Medicine and Pulmonary Medicine. &nbsp;My current interest is Critical Care Medicine. &nbsp;</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Multidisciplinary Critical Care Medicine (Medical, Surgical, Neurologic, Cardiothoracic).<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Role of the endothelium and its progenitors in the pathogenesis of disease.<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

5176

Biography

<p>Tihomir Stefanec, MD, is Attending Physician, Critical Care Medicine, Assistant Professor, Medicine and Neurology at Montefiore Einstein. His clinical focus is multidisciplinary critical care medicine including medical, surgical, neurologic and cardiothoracic critical care.</p><p>After earning his Doctor of Medicine from the University of Zagreb Medical School in Zagreb, Croatia in 1992, Dr. Stefanec completed an internal medicine internship and residency at Long Island College Hospital in 1997. He then completed a critical care medicine fellowship at Saint Vincent&rsquo;s Hospital and Medical Center in 1999. Following this, Dr. Stefanec completed a pulmonary medicine fellowship at Memorial Sloan Kettering Cancer Center in 2001.</p><p>Dr. Stefanec&rsquo;s past research focuses on the role of the endothelium and its progenitors in the pathogenesis of disease. His work has been published in peer-reviewed original publications, reviews, editorials and abstracts, and he has presented nationally.</p><p>Dr. Stefanec is board certified in Internal Medicine, Critical Care Medicine and Pulmonary Medicine by the American Board of Internal Medicine, as well as in Neurocritical Care by the United Council for Neurologic Subspecialties. He has been a Fellow of the American College of Chest Physicians since 2003, and is a member of the American Thoracic Society, the American College of Chest Physicians and the European Respiratory Society.</p>

Is Open Scheduling

Off

Jonathan M. Schwartz

https://assets.montefioreeinstein.org/profiles/images/Schwartz_Jonathan_MD_2x.jpg

First Name

Jonathan

Last Name

Schwartz

NPI

1215945738

Faculty ID

648

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Jonathan M. Schwartz is a board Certified Transplant Hepatologist. &nbsp;He is a graduate of Tel Aviv University, Sackler School of Medicine. He was an Internal Medicine Resident at Albert Einstein College of Medicine and a Fellow in Gastroenterology/Transplant Hepatology at the University of Washington in Seattle. &nbsp;He returned to New York in 2011 from Portland, Oregon where he served as an Associate Professor of Medicine at Oregon Health and Sciences University.</p>
<p>Dr. &nbsp;Schwartz has an interest in treating patients with acute and chronic liver diseases including those patients with advanced liver diseases who require liver transplantation.</p>
<p>He has a special interest in the multidisciplinary care of patients with liver tumors.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p><strong><br /></strong></p>
<ul>
<li>Estes JD, Stolpman D, Olyaei A, Ham JM, <strong>Schwartz JM</strong>, Orloff SL.&nbsp; High Prevalence of Potentially Hepatotoxic Herbal Supplement Use in Fulminant Hepatic Failure Patients. Arch Surg. 2003;138(8):852-8.</li>
<li><strong>Schwartz JM</strong>, Beymer C, Althaus SJ, Larson AM, Zaman A, Glickerman D, Kowdley KV.&nbsp; Cardiopulmonary Consequences of Transjugular Intrahepatic Portosystemic Shunts: Role of Increased Pulmonary Artery Pressure. J Clin Gastroenterol 2004;38(7):590-594.</li>
<li>Lim LL, Scarborough J, Thorne J, Graham E, Kempen J, Mackensen F, Nguyen Q D, Prabriputaloong T, Read R, Suhler EB, <strong>Schwartz JM</strong>, &nbsp;Smith JR. Uveitis in Patients with Autoimmune Hepatitis. Am J Ophthalmol. 2009;147(2):332-338.</li>
<li>O&rsquo;Glasser AY, Scott DA, Corless CL, Zaman A, Sasaki A, Gopal DV, Rayhill SC, Orloff SL, Ham JM, Rabkin JM, Flora K, Davies CH, Broberg CS, and <strong>Schwartz JM.</strong>Hepatic and Cardiac Iron Overload Among Patients with End-Stage Liver Disease Referred for Liver Transplantation. Clinical Transplantation. Clin Transplant. 2010 Sep-Oct;24(5):643-51.</li>
<li>Kanwal F, Befeler A, Chari R, Marrero J, Kahn J, Afdhal N, Morgan T, Roberts L, Mohanty SR, <strong>Schwartz J</strong>, Van Thiel D, Hassanein TI, Li J, Zeringue A, DiBisceglie A. Rate of Potentially Curative Treatment in Patients with Hepatocellular Carcinoma.&nbsp; Aliment Pharmacol Ther. 2012 Aug;36(3):257-65.</li>
<li>Bichoupan K1,&nbsp;<strong>Schwartz JM,</strong>&nbsp;Martel-Laferriere V,&nbsp;Giannattasio ER,&nbsp;Marfo K,&nbsp;Odin JA,&nbsp;Liu LU,&nbsp;Schiano TD,&nbsp;Perumalswami P,&nbsp;Bansal M,&nbsp;Gaglio PJ,&nbsp;Kalia H,Dieterich DT,&nbsp;Branch AD,&nbsp;Reinus JF. Effect of Fibrosis on Adverse Events in Patients with Hepatitis C Treated with Telaprevir. Aliment Pharmacol Ther.&nbsp;2014;39(2):209-16.</li>
<li><strong>Schwartz J</strong> and Carithers RL.&nbsp; Epidemiology and Etiologic Associations of Primary Hepatocellular Carcinoma.&nbsp; In Rose BD, editor. Up to date in Gastroenterology and Hepatology.&nbsp; Up to date, Inc. Wellesley, MA, Updated 2014.</li>
<li><strong>Schwartz JM </strong>and Carithers RL, Jr.&nbsp; Clinical features, diagnosis, and screening for primary hepatocellular carcinoma.&nbsp; Up to date in Gastroenterology and Hepatology.&nbsp; Up to date, Inc. Wellesley, MA, Updated 2014.</li>
<li>Curley SA, Stewart KE, <strong>Schwartz JM</strong>, Carthers RL, Jr.&nbsp; Nonsurgical therapies for localized hepatocellular carcinoma.&nbsp; Up to date, Inc. Wellesley, MA, Updated 2014.<strong>&nbsp;</strong></li>
<li><strong>Schwartz JM</strong>.&nbsp; Approach to the patient with a focal liver lesion.&nbsp; Up to date Inc Gastroenterology and Hepatology.&nbsp; Up to date, Inc. Wellesley, MA, Updated 2014.</li>
<li>Hartwell L and <strong>Schwartz JM.&nbsp; </strong>AsymptomaticLiver Chemistry Abnormalities. Journal of Clinical Outcomes Management. 2009; 16 (11): 525-34.</li>
<li>Urquhart J<strong>, Schwartz, JM.</strong> Hepatocellular Carcinoma Surveillance in a Western Population with Hepatitis B. Current Hepatitis Reports, 2011.</li>
<li><strong>Schwartz, JM </strong>and Reinus JF.&nbsp; Prevalence and Natural History of Alcoholic Liver Disease.&nbsp; Clinics in Liver Disease. 2012; 16 (4): 659-66.</li>
</ul>
<p>&nbsp;</p>

EMR ID

3842

Is Open Scheduling

Off

John F. Reinus

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/af2bc270-3a87-11ed-8158-59ecbd24247c.jpg

First Name

John

Last Name

Reinus

NPI

1669557435

Faculty ID

2404

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<FONT color=#000000>Clinical practice limited to liver diseases.&nbsp; Research on liver diseases and related topics.</FONT>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

PubMed.gov URL

Selected Publications

<p>&nbsp;</p>
<ol>
<li>Gaglio P, Moss N, McGaw C, Reinus JF. Direct-acting antiviral therapy for hepatitis C: Attitudes regarding future use. Dig Dis Sci. 2011; 56:1509-1515.</li>
<li>Flattau A, Olaywi M, Gaglio PJ, Marcus P, Meissner P, L Dorfman EB, Reinus JF. Social barriers to listing for adult liver transplantation: Their prevalence and association with program characteristics. Liver Transpl. 2011; 17:1167-1175.</li>
<li>Golowa YS, Cynamon J, Reinus JF, Kinkhabwala M, Abrams M, Jagust M, Chernyak V, Kaubisch A. Value of noncontrast CT immediately after transarterial chemoembolization of hepatocellular carcinoma with drug-eluting beads. J Vasc Interv Radiol. 2012; 23:1031-1035.</li>
<li>Schwartz JM, Reinus JF. Prevalence and natural history of alcoholic liver disease. Clin Liver Dis. 2012; 16:659-666. Review.</li>
<li>Kinkhabwala M, Lindower J, Reinus JF, Principe AL, Gaglio PJ. Expedited liver allocation in the United States: a critical analysis. Liver Transpl. 2013; 19: 1159-1165.</li>
<li>Bichoupan K, Schwartz JM, Martel-Laferriere V, Giannattasio ER, Marfo K, Odin JA, Liu LU, Schiano TD, Perumalswami P, Bansal M, Gaglio PJ, Kalia H, Dieterich DT, Branch AD, Reinus JF. Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. Aliment Pharmacol Ther. 2014; 39:209-216.</li>
<li>Izzy M, Jibara G, Aljanabi A, Alani M, Giannattasio E, Zaidi H, Said Z, Gaglio P, Wolkoff A, Reinus JF. Limited fibrosis progression but significant mortality in patients ineligible for interferon-based hepatitis C therapy.&nbsp; J Clin Exp Hepatol. 2016 Jun;6(2):100-8.</li>
<li>Chacko KR, Reinus J.&nbsp; Spectrum of alcoholic liver disease.&nbsp; Clin Liver Dis. 2016 Aug;20(3):419-27.</li>
<li>Chacko KR, Reinus J. Extrahepatic complications of nonalcoholic fatty liver disease.&nbsp; Clin Liver Dis. 2016 May;20(2):387-401. Review.</li>
</ol>
<p>&nbsp;</p>

EMR ID

3634

Biography

<p>John F. Reinus, MD, is Emeritus Medical Director, Liver Transplantation and Professor, Medicine at Montefiore Einstein. His work centers on liver transplantation, end-stage liver disease and viral hepatitis.</p><p>Dr. Reinus studied Pre-Medical Sciences at Columbia University before earning his Doctor of Medicine at Cornell Medical College in 1981. He then began an internal medicine internship at Bellevue Hospital Center, completing it in 1982. Following this, Dr. Reinus completed a residency in internal medicine at the same institution in 1984 before completing a hepatology fellowship at Emory University School of Medicine in 1985. He went on to complete a fellowship in gastroenterology at the same institution, finishing it in 1987. Dr. Reinus then completed a Transplant Hepatology Preceptorship at the Center for Liver Disease and Transplantation in 2006.</p><p>Building on his clinical focus, Dr. Reinus&rsquo; research is focused on liver diseases and related topics. His work has been published in peer-reviewed journals, books, chapters, reviews and abstracts, and he has presented at numerous conferences and meetings.</p><p>Dr. Reinus is board certified by the American Board of Medical Examiners in Internal Medicine, Gastroenterology and Transplant Hepatology. He is a fellow of the American Association for the Study of Liver Diseases and a member of the American Gastroenterological Association and the American Society of Transplantation.</p>

Is Open Scheduling

Off

Qiang Liu

https://assets.montefioreeinstein.org/profiles/images/physphoto/Liu_Qiang_MD_420x504.jpg

First Name

Qiang

Last Name

Liu

NPI

1780712133

Faculty ID

11561

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>My research interests include pancreatic and colonic carcinogenesis and causes of fatty liver disease. Clinical expertise is in the area of gastrointestinal and liver pathology including liver transplantation.&#160;</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4875

Is Open Scheduling

Off

Leslie Lee

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/b6b6c970-d504-11eb-9d97-7bd8ea6b93dc.jpg

First Name

Leslie

Last Name

Lee

NPI

1114269958

Faculty ID

15299

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

88499

Is Open Scheduling

Off